Terapet SA secures over CHF 2,3 million to bring its first product to market and to accelerate development of new nuclear imaging products

This funding supports the commercialization of Terapet’s first product, Qualγscan and the development of new nuclear imaging products.

Read the original press release here.

Terapet, a privately held Swiss MedTech company developing next generation imaging technology, is pleased to announce the new investment of CHF 2,3 million as the first closing of the Pre-Series A investment round. This funding supports the commercialization of Terapet’s first product, Qualγscan and the development of new nuclear imaging products.

The funding round was co-led by EFI Lake Geneva Ventures and Nina Capital with support of all the existing shareholders including Fongit, Venturekick and the founders.

Terapet’s novel technology, developed in collaboration with leading research institutes CERN and Politecnico di Milano, has the potential to make nuclear medicine imaging more accessible for every patient in the future.
The first product, Qualγscan is a novel proton therapy quality assurance device which, for the first time, will provide a way of assessing the real-time dose distribution. The device will be validated together with clinical partners at the Karolinska Institute and Skandion Clinic. In the coming years, the same technology will enable medical doctors to monitor the delivered dose inside the patients during cancer treatment: in-vivo, non-invasively, in 3D and real-time.

“With our solution, we will eliminate one of the biggest obstacles to particle therapy: ensuring that every patient receives the right dose, every time,” says Dr. Christina Vallgren, CEO of Terapet. “We look forward to showcasing our first product to the particle therapy community at this year’s PTCOG in Madrid. This funding is essential to support the marketing and sales campaign for Qualγscan.”

Terapet also welcomes new members to its Board of Directors: Giovanni Leo from EFI Lake Geneva Ventures and Sebastian Anastassiou from Nina Capital.

"I am thrilled to join the board of Terapet and contribute to the development of the next generation of nuclear imaging products. As a MedTech professional, I have long been passionate about the potential of medical imaging to improve patient outcomes and I believe that Terapet is uniquely positioned to lead the way in this space. I look forward to working alongside the talented team at Terapet to help drive innovation, enhance our technology, and ultimately, make a meaningful impact on the healthcare industry." – says Giovanni Leo, partner of EFI Lake Geneva Ventures.

Principal from Nina Capital, Sebastian Anastassiou who will also join the new board, said, “I am excited to continue supporting Terapet towards realizing their vision of drastically improving patient outcomes by developing the future of nuclear imaging. With solid technology foundations out of CERN and a stellar team, we have all the right ingredients to work together towards true healthcare impact.”